• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Rare rheuma­tol­ogy dis­ease in spot­light af­ter Sanofi, Re­gen­eron nab first drug ap­proval, more in pipeline po­ten­tials

3 years ago
Pharma
Marketing

In­flaRx plans to launch Covid an­ti­body with five-fig­ure price tag

3 years ago
Pharma
FDA+

Genen­tech notch­es ‘steady progress’ on lat­est di­ver­si­ty and in­clu­sion re­port card

3 years ago
Pharma
Marketing

Sanofi breaks ground on BAR­DA-backed, $160M vac­cine man­u­fac­tur­ing site in Penn­syl­va­nia

3 years ago
Pharma
Manufacturing

Am­gen's deno­sum­ab shows promise in small, NIH-fund­ed rare bone dis­ease study

3 years ago
R&D

FDA clos­es out se­ries of pa­tient-fo­cused drug de­vel­op­ment guid­ance

3 years ago
FDA+

In­cyte links arms with tiny Bio­th­eryx for pro­tein de­grad­er deal, tar­get­ing can­cer

3 years ago
Deals
R&D

Gink­go snaps up gene ther­a­py vec­tor as­sets from Stride­Bio

3 years ago
Deals
R&D

Hedge fund slams Ex­elix­is for R&D man­age­ment, launch­es proxy fight for board seats (up­dat­ed)

3 years ago
People

PureTech wants to buy back its weight loss pill spin­out af­ter lack­lus­ter SPAC

3 years ago
People
Deals

'Have to keep up this pace': As new Vir CEO, Mar­i­anne De Backer eyes ex­pan­sion be­yond in­fec­tious dis­ease

3 years ago
People

As­traZeneca's Lyn­parza-Imfinzi com­bo clears PhI­II tri­al in ovar­i­an can­cer

3 years ago
R&D

J&J spin­out files sec­ond bank­rupt­cy at­tempt in $8.9B bid to set­tle talc law­suits

3 years ago
Pharma
Law

Es­tée Laud­er's fam­i­ly in­jects $200M in­to Alzheimer’s Drug Dis­cov­ery Foun­da­tion

3 years ago
R&D

Fol­low­ing clin­i­cal set­backs, NGM Bio lays off 33% of staffers as founder de­parts

3 years ago
People

Prox­y­gen and Mer­ck strike li­cense deal worth up to $2.55B for pro­tein degra­da­tion

3 years ago
Startups
Deals

In­flaRx wins FDA emer­gency use au­tho­riza­tion for Covid an­ti­body

3 years ago
Pharma
FDA+

Pfiz­er ac­cused of Covid-19 vac­cine patent in­fringe­ment again, this time by Ar­bu­tus and Genevant

3 years ago
Pharma
Law

J&J’s Janssen takes doc­tors ‘be­yond the text­book’ to teach about pso­ri­a­sis in peo­ple of col­or

3 years ago
Pharma
Marketing

Ther­mo Fish­er set to shut­ter a site in New Jer­sey, lay off 100+ peo­ple

3 years ago
People
Pharma

FDA re­quires opi­oid man­u­fac­tur­ers to pro­vide mail-back dis­pos­al op­tion

3 years ago
Pharma
FDA+

Delaware court dis­miss­es Mer­ck­'s talc li­a­bil­i­ty suit against Bay­er

3 years ago
Pharma
Law

Ake­bia touts new da­ta on ane­mia drug a year af­ter re­jec­tion

3 years ago
R&D
Pharma

Mar­ket­ingRx roundup: Pfiz­er lead­ers join speak­er line­up at Cannes ad fest; Jazz re­ups sleep spon­sor­ship

3 years ago
Pharma
Marketing
First page Previous page 362363364365366367368 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times